Dr. Swetha Kambhampati, MD | Duarte, CA ...

Dr. Swetha Kambhampati, MD

Claim this profile

City of Hope Medical Center

Studies Follicular Lymphoma
Studies Non-Hodgkin's Lymphoma
6 reported clinical trials
8 drugs studied

Area of expertise

1

Follicular Lymphoma

Swetha Kambhampati, MD has run 4 trials for Follicular Lymphoma. Some of their research focus areas include:

CD19 positive
CD20 positive
2

Non-Hodgkin's Lymphoma

Swetha Kambhampati, MD has run 3 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:

Stage IV
CD19 positive
CD20 positive

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Image of trial facility.

City Of Hope At Irvine Lennar

Clinical Trials Swetha Kambhampati, MD is currently running

Image of trial facility.

Epcoritamab + Tazemetostat

for Follicular Lymphoma

This phase II trial tests the safety, side effects and effectiveness of epcoritamab and tazemetostat in treating patients with grade I-IIIa follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab is a bispecific monoclonal antibody that binds to two different antigens on the surface of cancer cells that may help the body's immune system attack the cancer and may interfere with the ability of the cancer cells to grow and spread. Tazemetostat, a EZH2 inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving epcoritamab and tazemetostat may be safe, tolerable and/or effective in treating patients with relapsed or refractory grade I-IIIa follicular lymphoma.

Recruiting

1 award

Phase 2

9 criteria

Image of trial facility.

Loncastuximab Tesirine + Mosunetuzumab

for Lymphoma

This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, loncastuximab, linked to a toxic agent called tesirine. Loncastuximab attaches to anti-CD19 cancer cells in a targeted way and delivers tesirine to kill them. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving loncastuximab tesirine with mosunetuzumab may help treat patients with relapsed or refractory diffuse large B-cell lymphoma.

Recruiting

1 award

Phase 2

More about Swetha Kambhampati, MD

Clinical Trial Related

7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Swetha Kambhampati, MD has experience with

  • Epcoritamab
  • Tazemetostat
  • Lenalidomide
  • Loncastuximab Tesirine
  • Mosunetuzumab
  • PRO1160

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Swetha Kambhampati, MD specialize in?

Is Swetha Kambhampati, MD currently recruiting for clinical trials?

Are there any treatments that Swetha Kambhampati, MD has studied deeply?

What is the best way to schedule an appointment with Swetha Kambhampati, MD?

What is the office address of Swetha Kambhampati, MD?

Is there any support for travel costs?